Skip to main content
ARS Home » Southeast Area » Fayetteville, Arkansas » Poultry Production and Product Safety Research » Research » Publications at this Location » Publication #419018
Research Project: Multi-hurdle Approaches for Controlling Foodborne Pathogens in Poultry

Location: Poultry Production and Product Safety Research

Title: Electron beam (eBeam)-killed multivalent vaccines to control Clostridium perfringens and Mycoplasma gallisepticum in chickens

Author
item Jesudhasan, Palmy
item Donoghue, Ann
item Arsi, Komala
item Evans, Jeffrey
item Purswell, Joseph
item NAZMI, ALI - The Ohio State University
item PILLAI, SURESH - Texas A&M Agrilife
item ASSUMPCAO, ANNA - University Of Arkansas

Submitted to: Meeting Abstract
Publication Type: Abstract Only
Publication Acceptance Date: 10/21/2024
Publication Date: 1/18/2025
Citation: Jesudhasan, P., Donoghue, A.M., Arsi, K., Evans, J.D., Purswell, J.L., Nazmi, A., Pillai, S.D., Assumpcao, A. 2025. Electron beam (eBeam)-killed multivalent vaccines to control Clostridium perfringens and Mycoplasma gallisepticum in chickens. Abstract. 2025 Annual Conference of Research Workers in Animals Diseases. Chicago, Illinois, January 18-21, 2025.

Interpretive Summary:

Technical Abstract: Objectives: (a) To prepare a multivalent Clostridium perfringens (CP) (mixture of 6 or more strains) vaccine using eBeam technology and determine its efficacy in protecting broiler chickens when challenged with homologous and heterologous strains of CP. (b) To prepare a multivalent Mycoplasma gallisepticum (MG) (mixture of 6 or more strains) vaccine using eBeam technology and determine its efficacy in protecting layer chickens when challenged with homologous and heterologous strains of MG. Methods: All CP poultry isolates will be grown independently in anaerobic conditions at 37°C using a Fluid Thioglycolate (FTG) medium. All MG strains will be grown independently in aerobic conditions at 37°C using Frey’s medium and pooled in equal proportions. Both CP strains and MG strains will be exposed to lethal eBeam exposure at Texas A&M University. The eBeam-exposed-CP and MG cells will be tested in vitro and in vivo assays to test the effects of eBeam. We will conduct bird studies to test the efficacy of eBeam-inactivated CP and MG vaccines. Results: We have obtained results from in vitro assays of CP and MG strains exposed to lethal eBeam dose. Results indicate that the lethal eBeam dose did not affect cell membrane of both CP and MG strains. Conclusions: In general, the eBeam dose used for pathogen inactivation does not cause damage to proteins. So when we exposed CP and MG strains to lethal dose of eBeam did not affect membrane proteins. The eBeam-exposed CP and MG strains could be a potential vaccine candidate. To test the efficacy of eBeam-inactivated CP and MG strains, we have to conduct bird studies.